[go: up one dir, main page]

PE20230162A1 - Derivados espirancos sustituidos de cadena lineal - Google Patents

Derivados espirancos sustituidos de cadena lineal

Info

Publication number
PE20230162A1
PE20230162A1 PE2022001149A PE2022001149A PE20230162A1 PE 20230162 A1 PE20230162 A1 PE 20230162A1 PE 2022001149 A PE2022001149 A PE 2022001149A PE 2022001149 A PE2022001149 A PE 2022001149A PE 20230162 A1 PE20230162 A1 PE 20230162A1
Authority
PE
Peru
Prior art keywords
spiranch
isopropyl
protein
compounds
linear chain
Prior art date
Application number
PE2022001149A
Other languages
English (en)
Inventor
Wei Cai
Xuedong Dai
Olivier Alexis Georges Querolle
Johannes Wilhelmus John F Thuring
Yingtao Liu
Lianzhu Liu
Yanping Xu
Liqiang Fu
Ming Li
Lichao Fang
Xiangjun Deng
Qiwu Zhao
Kangying Li
Alicia Tee Fuay Ng
Nicolas Freddy J Darville
Edward Cleator
Gregor Thomas Urbanietz
William Marc Maton
Vineet Pande
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20230162A1 publication Critical patent/PE20230162A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a compuestos de Formula (I), los tautomeros o formas estereoisomericas de estos; en donde R1a representa -C(=O)-NRxaRxb, Het, entre otros; Het representa un anillo aromatico monociclico de 5 a 6 miembros, entre otros; R1b representa F o Cl; Y1 representa -CR5aR5b-, -O- o -NR5c-; R2 se selecciona de -O-alquilo C1-4 y -NR7aR7b; U es N o CH; n1, n2, n3 y n4 son 1 y 2; X1 es CH; X2 es N y R4 es isopropilo. Un compuesto seleccionado es (R)-(4-(6-(6-(2-(etil(isopropil)carbamoil)-4-fluorofenoxi)-1,2,4-triazin-5-il)-2,6-diazaespiro[3.4]octan-2-il)-5-metilhexil)carbamato de tert-butilo. Asimismo, refiere a una composicion farmaceutica que los comprende. Dichos compuestos son inhibidores de la interaccion proteina/proteina de la menina/MLL, siendo utiles para el tratamiento de cancer, que incluye leucemia, sindrome mielodisplasico (SMD) y neoplasias mieloproliferativas (NMP); y diabetes.
PE2022001149A 2019-12-19 2020-12-17 Derivados espirancos sustituidos de cadena lineal PE20230162A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019126760 2019-12-19
US202062961775P 2020-01-16 2020-01-16
CN2020126595 2020-11-04
PCT/CN2020/137266 WO2021121327A1 (en) 2019-12-19 2020-12-17 Substituted straight chain spiro derivatives

Publications (1)

Publication Number Publication Date
PE20230162A1 true PE20230162A1 (es) 2023-02-01

Family

ID=76476870

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001149A PE20230162A1 (es) 2019-12-19 2020-12-17 Derivados espirancos sustituidos de cadena lineal

Country Status (21)

Country Link
US (1) US12473295B2 (es)
EP (1) EP4077312A4 (es)
JP (2) JP7554829B2 (es)
KR (1) KR20220118500A (es)
CN (4) CN118255774A (es)
AU (1) AU2020404305A1 (es)
CA (1) CA3161045A1 (es)
CL (3) CL2022001583A1 (es)
CO (1) CO2022009085A2 (es)
CR (1) CR20220346A (es)
DO (1) DOP2022000125A (es)
EC (1) ECSP22054700A (es)
IL (1) IL293965A (es)
JO (1) JOP20220154A1 (es)
MX (1) MX2022007652A (es)
PE (1) PE20230162A1 (es)
PH (1) PH12022551502A1 (es)
TW (2) TWI878414B (es)
UA (1) UA129208C2 (es)
UY (1) UY38988A (es)
WO (1) WO2021121327A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
CA3165168A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JOP20220154A1 (ar) 2019-12-19 2023-01-30 Janssen Pharmaceutica Nv مشتقات سبيرو بسلسلة مستقيمة بها استبدال
CN117321049A (zh) 2021-05-08 2023-12-29 詹森药业有限公司 取代的螺环衍生物
JP2024518425A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
WO2022237720A1 (en) 2021-05-11 2022-11-17 Janssen Pharmaceutica Nv Combination therapies
CA3214861A1 (en) 2021-05-11 2022-11-17 Nikki DASKALAKIS Combination therapies
CR20230605A (es) 2021-06-01 2024-05-24 Janssen Pharmaceutica Nv Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
PH12023553300A1 (en) * 2021-06-17 2024-04-08 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN116829559A (zh) * 2021-12-03 2023-09-29 烨辉医药科技(上海)有限公司 羰基取代的二氮杂螺化合物及其用途
JP2025530791A (ja) * 2022-09-02 2025-09-17 ハッチメッド リミティド トリアジン化合物及びその使用
EP4622635A1 (en) 2022-11-24 2025-10-01 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024218072A1 (en) 2023-04-17 2024-10-24 Janssen Pharmaceutica Nv Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder.
WO2025082444A2 (en) 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer
CN120365200B (zh) * 2025-04-18 2025-11-11 北京蓝博特科技有限公司 一种(s)-2-(3,5-二甲基苯基)吡咯烷盐酸盐的制备方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2791732B2 (ja) * 1992-04-02 1998-08-27 小野薬品工業株式会社 ３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
PL372145A1 (en) 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
CA2509406C (en) 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
AU2006206738A1 (en) 2005-01-19 2006-07-27 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP5343975B2 (ja) 2008-10-06 2013-11-13 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及びプログラム
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
KR20120060217A (ko) 2009-08-20 2012-06-11 바이엘 크롭사이언스 아게 살비제 및 살충제로 사용하기 위한 3-트리아졸릴페닐-치환된 설파이드 유도체
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
EP2590981B1 (en) 2010-07-09 2014-09-03 Leo Pharma A/S Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
GB201021623D0 (en) 2010-12-21 2011-02-02 Isis Innovation Detection of acute myeloid leukaemia
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
EP2620094B1 (en) 2011-08-01 2015-10-14 Olympus Corporation Apparatus for displaying shape of insertion portion
BR112014005793A2 (pt) 2011-09-14 2017-03-28 Proximagen Ltd compostos inibidores de enzimas
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
AU2013347538B2 (en) 2012-11-16 2017-04-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100730A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US9216993B2 (en) 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
PT3060550T (pt) 2013-10-21 2019-08-27 Merck Patent Gmbh Compostos de heteroarilo como inibidores de btk e utilizações dos mesmos
US9708568B2 (en) 2014-05-06 2017-07-18 The Procter & Gamble Company Fragrance compositions
WO2015191701A1 (en) 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN105330698B (zh) * 2014-07-04 2019-05-28 齐鲁制药有限公司 螺环芳基磷氧化物和硫化物
JP6487527B2 (ja) * 2014-07-04 2019-03-20 チル ファーマシューティカル カンパニー リミテッド スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
US20170275302A1 (en) * 2014-10-14 2017-09-28 Alexander Pasternak Inhibitors of the renal outer medullary potassium channel
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
MY199935A (en) 2014-12-18 2023-11-29 Wells Therapeutics Inc Solid state forms of fused heteroaromatic pyrrolidinones
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CN108779116A (zh) 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
WO2017132398A1 (en) 2016-01-26 2017-08-03 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
SG11201809714TA (en) 2016-05-02 2018-11-29 Univ Michigan Regents Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
KR20250079083A (ko) 2016-06-10 2025-06-04 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
KR102339881B1 (ko) 2016-09-06 2021-12-14 가부시끼가이샤 쓰리본드 열경화형 도전성 접착제
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
MX2019003091A (es) 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.
EA201990699A1 (ru) 2016-10-05 2019-09-30 Янссен Фармацевтика Нв Спиробициклические ингибиторы взаимодействия менин–mll
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のアゼパン阻害剤
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN117298275A (zh) 2017-03-24 2023-12-29 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
BR112019026483A2 (pt) 2017-06-16 2020-07-14 Beta Pharma, Inc. formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais
KR20200027548A (ko) 2017-07-09 2020-03-12 바이오사이트 리미티드 병용 암 요법
EP3684361A4 (en) * 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
GB201720077D0 (en) 2017-12-01 2018-01-17 Univ Oxford Innovation Ltd Leukaemic stem cell
EP3728260A4 (en) 2017-12-20 2021-08-11 Janssen Pharmaceutica NV SPIRO EXO-AZA INHIBITORS OF MENIN-MLL INTERACTION
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
EP3845533A4 (en) 2018-08-27 2022-04-27 Sumitomo Dainippon Pharma Co., Ltd. OPTICALLY ACTIVE AZABICYCLIC DERIVATIVE
EP3856173A4 (en) 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMOPATHY MALIGNANCE WITH MENIN INHIBITORS
JP7594787B2 (ja) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CN113966217B (zh) 2019-06-14 2025-07-04 达萨玛治疗公司 Sarm1抑制剂
KR20210078631A (ko) 2019-12-18 2021-06-29 솔루스첨단소재 주식회사 유기 화합물 및 이를 이용한 유기 전계 발광 소자
JOP20220154A1 (ar) 2019-12-19 2023-01-30 Janssen Pharmaceutica Nv مشتقات سبيرو بسلسلة مستقيمة بها استبدال
CN111297863B (zh) 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
JP2023522166A (ja) 2020-04-07 2023-05-29 シンダックス ファーマシューティカルズ， インコーポレイテッド メニン阻害剤とｃｙｐ３ａ４阻害剤との組合せ、およびその使用方法
AU2021389180A1 (en) 2020-11-30 2023-06-29 Astellas Pharma Inc. Heteroaryl carboxamide compound
JP2024518425A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
CN117321049A (zh) 2021-05-08 2023-12-29 詹森药业有限公司 取代的螺环衍生物
WO2022237720A1 (en) 2021-05-11 2022-11-17 Janssen Pharmaceutica Nv Combination therapies
CA3214861A1 (en) 2021-05-11 2022-11-17 Nikki DASKALAKIS Combination therapies
EP4337329A4 (en) 2021-05-12 2025-01-01 Syndax Pharmaceuticals, Inc. COMBINATIONS FOR CANCER TREATMENT
CR20230605A (es) 2021-06-01 2024-05-24 Janssen Pharmaceutica Nv Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
PH12023553300A1 (en) 2021-06-17 2024-04-08 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN116829559A (zh) * 2021-12-03 2023-09-29 烨辉医药科技(上海)有限公司 羰基取代的二氮杂螺化合物及其用途
JP2025503385A (ja) 2021-12-15 2025-02-04 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化
EP4472637A4 (en) * 2022-02-04 2025-12-31 Kura Oncology Inc TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENNIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS
CN120514709A (zh) 2022-05-09 2025-08-22 赛达克斯制药股份有限公司 用于治疗癌症的menin-mll抑制剂
WO2024114662A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Cyclobutyl substituted bicyclic compounds
CN120322230A (zh) 2022-11-30 2025-07-15 詹森药业有限公司 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合
JP2025541695A (ja) 2022-11-30 2025-12-23 ヤンセン ファーマシューティカ エヌ．ベー． 置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体
JP2025540762A (ja) 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ阻害剤及びｂｃｌ－２阻害剤を含む組み合わせ
WO2024218072A1 (en) 2023-04-17 2024-10-24 Janssen Pharmaceutica Nv Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder.

Also Published As

Publication number Publication date
EP4077312A1 (en) 2022-10-26
PH12022551502A1 (en) 2023-04-24
JOP20220154A1 (ar) 2023-01-30
CL2023001531A1 (es) 2023-11-03
UA129208C2 (uk) 2025-02-05
CA3161045A1 (en) 2021-06-24
AU2020404305A1 (en) 2022-08-04
US12473295B2 (en) 2025-11-18
KR20220118500A (ko) 2022-08-25
TW202525813A (zh) 2025-07-01
CN118255774A (zh) 2024-06-28
US20230142285A1 (en) 2023-05-11
DOP2022000125A (es) 2022-08-31
JP2023506530A (ja) 2023-02-16
CN114867721A (zh) 2022-08-05
CO2022009085A2 (es) 2022-07-08
WO2021121327A1 (en) 2021-06-24
CR20220346A (es) 2022-10-26
TW202138367A (zh) 2021-10-16
UY38988A (es) 2021-06-30
JP2024138279A (ja) 2024-10-08
ECSP22054700A (es) 2022-11-30
TWI878414B (zh) 2025-04-01
IL293965A (en) 2022-08-01
CN118255773A (zh) 2024-06-28
CL2022001583A1 (es) 2023-02-03
JP7554829B2 (ja) 2024-09-20
CN118344372A (zh) 2024-07-16
MX2022007652A (es) 2022-09-23
EP4077312A4 (en) 2024-01-17
JP7781961B2 (ja) 2025-12-08
CL2023001530A1 (es) 2023-11-03

Similar Documents

Publication Publication Date Title
PE20230162A1 (es) Derivados espirancos sustituidos de cadena lineal
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
CL2021001859A1 (es) Inhibidores de la pcsk9 y métodos de uso de los mismos
AR048741A1 (es) Derivados de omega-carboxiaril difenil urea sustituida
ECSP109958A (es) Derivados de pirimidina 934
AR045414A1 (es) Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
UY29176A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.
AR074109A1 (es) Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil.
CO2022004305A2 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
AR039256A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2021000031A1 (es) Compuestos heterocíclicos antihelmínticos
DE602007004740D1 (de) Antibiotische spiroderivate
PE20242359A1 (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
CO5601029A2 (es) Inhibidores no nucleosidos de transcriptasa inversa i para el tratamiento de enfermedades mediadas por vih
CL2020002588A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016)
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
GT200300218A (es) Agonistas ppar quirales
AR069781A1 (es) Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia.
CL2023003091A1 (es) Compuestos de péptidos similares al glucagón